Latest Content

In a trial of 171 women, app-based self-acupressure improved fatigue vs usual care, offering a low-cost option for ovarian cancer survivors.

FDA removal of an exclusion allows Yescarta use in primary CNS lymphoma, showing safety and strong efficacy in relapsed disease.

My daughter is happy to tell her story so that others can learn that there is hope in the face of despair.

The U.S. FDA has granted traditional approval to Braftovi with Erbitux and chemo for adults with BRAF V600E metastatic colorectal cancer.

Five-year follow-up of cryoablation for small kidney tumors shows high recurrence-free rates and a minimally invasive option for select patients.

FDA granted fast track designation to AKY-1189 for adults with metastatic urothelial cancer after systemic therapy, aiming to speed development of the investigational drug.

The FDA granted fast track status to ART6043 plus Lynparza for patients with gBRCA-mutated HER2-negative breast cancer to accelerate drug development.

In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma.

Cancer-related fatigue may persist despite improved sleep or treated depression, underscoring it as a distinct and complex symptom.

Rodney Haring discusses Indigenous navigation, partnerships and prevention strategies to reduce cancer disparities and improve equity in Native communities

The FDA cleared an IND for FG001, allowing a U.S. trial in high-grade glioma, with first patient enrollment expected in second quarter of 2026.

Genentech announces FDA acceptance of giredestrant plus Afinitor for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer treatment.